Literature DB >> 1271976

Comparative antilipidemic effects of various ethyl 5-substituted benzofuran-, 2,3-dihydrobenzofuran-, and 3(2H)-benzofuranone-2-carboxylate analogs of clofibrate in a triton hyperlipidemic rat model.

D T Witiak, H A Newman, G K Poochikian, W Loh, S K Sankarappa.   

Abstract

The antilipidemic properties of certain benzofuran-, 2,3-dihydrobenzofuran-, and 3(2H)-benzofuranone-2-carboxylate analogs of clofibrate in a hyperlipidemic rat model are described. The hyperlipidemia was induced by intraperitoneal injection of Triton WR-1339. The results were analyzed in light of structural modifications as well as the lipid solubility of substituted compounds as assessed by a consideration of calculated log P values. Comparisons are made between the activity of these compounds and the activity of related cyclic analogs previously reported. Among the various compounds tested, only the 5-C1 and phenylsybstituted dihydrobenzofurans were selective against elevated serum cholesterol levels in this animal model. The data presented support the hypothesis that the cholesterol and triglyceride lowering activity of clofibrate related analogs in this animal model may be separated through a consideration of log P, conformational, and electronic changes. The proposal is advanced that relatively minor structural modification of clofibrate related analogs may lead to compounds which are not only selective in the Triton model but also to compounds which are likely to exert their effects by differing modes of action.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1271976     DOI: 10.1007/BF02532845

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  16 in total

Review 1.  Hypolipidaemic agents.

Authors:  R Howe
Journal:  Adv Drug Res       Date:  1974

Review 2.  Laboratory models for atherosclerosis.

Authors:  D Kritchevsky
Journal:  Adv Drug Res       Date:  1974

3.  Hypolipidemic substituted 1,3-benzodioxole-2-carboxylates.

Authors:  J M Grisar; G P Claxton; R A Parker; F P Palopoli; T Kariya
Journal:  J Med Chem       Date:  1974-07       Impact factor: 7.446

4.  Differential effects of benzodioxane, chroman and dihydrobenzofuran analogs of clofibrate in a Triton hyperlipemic rat model.

Authors:  H A Newman; W P Heilman; D T Witiak
Journal:  Lipids       Date:  1973-07       Impact factor: 1.880

5.  "Aromatic" substituent constants for structure-activity correlations.

Authors:  C Hansch; A Leo; S H Unger; K H Kim; D Nikaitani; E J Lien
Journal:  J Med Chem       Date:  1973-11       Impact factor: 7.446

Review 6.  The treatment of hyperlipidemia.

Authors:  R S Lees; D E Wilson
Journal:  N Engl J Med       Date:  1971-01-28       Impact factor: 91.245

7.  Hypocholesterolemic indole-2-carboxylic acids.

Authors:  T Kariya; J M Grisar; N L Wiech; T R Blohm
Journal:  J Med Chem       Date:  1972-06       Impact factor: 7.446

Review 8.  Fat transport in lipoproteins--an integrated approach to mechanisms and disorders.

Authors:  D S Fredrickson; R I Levy; R S Lees
Journal:  N Engl J Med       Date:  1967-01-12       Impact factor: 91.245

Review 9.  Fat transport in lipoproteins--an integrated approach to mechanisms and disorders.

Authors:  D S Fredrickson; R I Levy; R S Lees
Journal:  N Engl J Med       Date:  1967-02-02       Impact factor: 91.245

Review 10.  Fat transport in lipoproteins--an integrated approach to mechanisms and disorders.

Authors:  D S Fredrickson; R I Levy; R S Lees
Journal:  N Engl J Med       Date:  1967-01-19       Impact factor: 91.245

View more
  2 in total

1.  Antilipidemic activity of 4-oxo-functionalized ethyl 6-chlorochroman-2-carboxylate analogs and a related tricyclic lactone in three rat models.

Authors:  R C Cavestri; J A Minatelli; J R Baldwin; W Loh; D R Feller; H A Newman; C L Sober; D T Witiak
Journal:  Lipids       Date:  1981-01       Impact factor: 1.880

2.  The hypolipidemic activity of furoic Acid and furylacrylic Acid derivatives in rodents.

Authors:  I H Hall; W L Williams; K A Rhyne; M Knowles
Journal:  Pharm Res       Date:  1985-09       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.